International AIDS Vaccine Initiative - Partnerships

Partnerships

To address major obstacles in AIDS vaccine development, IAVI partners with HIV researchers from around the world in AIDS vaccine consortia. Foremost is the Neutralizing Antibody Consortium, a network dedicated to discovering and understanding broadly neutralizing antibodies against HIV and using that knowledge in the design of vaccines. IAVI also operates the Innovation Fund – a financing mechanism established jointly with the Bill & Melinda Gates Foundation – which seeks out and supports using new technologies to solve major issues hampering AIDS vaccine development.

The organization also partners with individuals and organizations in developing countries to conduct epidemiological studies, social-science research, educational initiatives, voluntary counseling and testing consultations and capacity-building to ensure transparent and effective clinical trial processes. Partners include the Kenya AIDS Vaccine Initiative, Rwanda’s Project San Francisco, the Uganda Virus Research Institute, the Indian Council of Medical Research and the Zambia–Emory HIV Research Project. In some countries where IAVI is not sponsoring clinical studies, the organization works with partners to support AIDS vaccine research and advocacy efforts.

IAVI also partners with other organizations to analyze how improved public policies could help to accelerate AIDS vaccine R&D and ensure rapid global access to a future vaccine. As part of the organization’s advocacy in developing countries, IAVI supports the India-Brazil-South Africa trilateral agreement as a vehicle for spurring cooperation in vaccine development among countries with growing biomedical research and manufacturing capabilities. The organization is a founding member of the Global HIV Vaccine Enterprise, an alliance of independent organizations working towards an HIV vaccine. It is also a member of the Global Health Technologies Coalition, an alliance of more than 30 non-profit groups that aims to increase awareness of the urgent need for technologies that save lives in developing countries.